[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_margin_tablet="5%|auto|5%|auto|false|false" custom_margin_phone="5%|auto|5%|auto|false|false" custom_margin_last_edited="on|phone" custom_padding="50px|50px|50px|50px|true|true" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/Andrew.jpg" title_text="Andrew" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|desktop" module_alignment="center" border_radii="on|250px|250px|250px|250px" border_width_all="6px" border_color_all="#FFFFFF" border_radii_tablet="on|251px|251px|251px|251px" border_radii_phone="on|251px|251px|251px|251px" border_radii_last_edited="on|desktop" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" global_colors_info="{}"]

Andrew Levin, MD, PhD

Interim Chief Executive Officer

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" custom_padding_tablet="" custom_padding_phone="|0px||0px|false|false" custom_padding_last_edited="on|tablet" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]

Andrew Levin is the interim Chief Executive Officer of Lusaris Therapeutics and a Partner and Managing Director on the investment team at RA Capital Management. Andrew joined RA in 2015 and spearheads a drug discovery effort that has led to the formation of several new companies. Beginning in 2012, and prior to joining RA, he was a Vice President at H.I.G. BioVentures. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in biomedical engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/Neil.png" title_text="Neil" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" module_alignment_tablet="center" module_alignment_phone="center" module_alignment_last_edited="on|tablet" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" global_colors_info="{}"]

Neil Buckley, MS

Chief Operating Officer

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]Neil Buckley is a life sciences entrepreneur, company builder, and drug developer. Prior to Lusaris Therapeutics, Neil was a founder or founding team member of six companies incubated within RA Ventures including Eliem Therapeutics ($ELYM), Aerovate Therapeutics ($AVTE), Imbria Pharmaceuticals, and Athenen Therapeutics (acquired by Eliem). Neil spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. Previously, Neil was Director, Business Development and Project Management at CiVentiChem (Acquired by Sterling Pharma Solutions). He holds a MS from Northeastern University and a BA from Hamilton College.[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/Ed2.png" title_text="Ed2" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" custom_margin_tablet="" custom_margin_phone="" custom_margin_last_edited="on|tablet" module_alignment_tablet="center" module_alignment_phone="center" module_alignment_last_edited="on|tablet" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" global_colors_info="{}"]

Ed Monaghan, PhD

Chief Development Officer

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]Ed Monaghan has 30 years of drug development experience in both preclinical and clinical development, as well as regulatory affairs for pharmaceutical and biotechnology companies. Prior to Lusaris Therapeutics, Ed spent seven years at RA Ventures as Chief Development Officer, where he built the development team and oversaw the development of six compounds from discovery through clinical development and the formation of several new companies. Ed began his pharmaceutical career working in clinical development with neurologically active compounds at Allergan, CoCensys, and Serono. Since 2002, he has been working in start-up pharma companies, including co-founding Thesan Pharmaceuticals and NeoKera, where he assumed responsibilities for all development activities, including regulatory affairs. Ed holds a PhD in neuroscience from the University of California Berkeley, an MS in psychology from Villanova University, and a BA from La Salle University.[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/212FA1C680E9E9CA.png" title_text="212FA1C680E9E9CA" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" module_alignment_tablet="center" module_alignment_phone="center" module_alignment_last_edited="on|tablet" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" global_colors_info="{}"]

Ramin Farzaneh-Far, MD

Acting Chief Medical Officer

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]Ramin Farzaneh-Far is acting Chief Medical Officer of Lusaris Therapeutics and a Venture Partner at RA Capital where he works closely with RA’s Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center. Ramin completed his internal medicine residency at Brigham & Women’s Hospital in Boston and trained in cardiovascular medicine at UCSF. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF.[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/Kat.jpg" title_text="Kat" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" module_alignment_tablet="center" module_alignment_phone="center" module_alignment_last_edited="on|phone" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" global_colors_info="{}"]

Kat Riesen, CPA

Chief Financial Officer

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]Kat Riesen is the Chief Financial Officer of Lusaris Therapeutics and the Vice President, Finance at RA Ventures. Kat’s primary responsibility is supporting new companies, portfolio companies, and executives within RA Ventures, focusing on strategic finance. Prior to joining RA Ventures, Kat was a Partner at van den Boom & Associates where she provided accounting and finance services including new company formation through IPO and public company accounting support, SOX compliance implementation, and financial modeling to several public and private life science companies. Before entering the life science space, Kat held various accounting roles in the retail industry and started her career at Ernst & Young. Kat has a BS in business administration, majoring in accounting from the University of Minnesota, Carlson School of Management. She is a CPA.[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/Ned2.png" title_text="Ned2" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" module_alignment_tablet="center" module_alignment_phone="center" module_alignment_last_edited="on|tablet" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.1" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]

Ned Whittemore, PhD

Vice President, Regulatory Affairs

[/et_pb_text][et_pb_text _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"]

Ned Whittemore is a trained neuroscientist with more than 25 years of diverse experience in pharmaceutical drug discovery, preclinical and clinical development, and regulatory affairs. For the past 11 years, Ned has been working in regulatory affairs, building a successful track record of regulatory submissions to FDA and EMA, most recently as the Vice President, Regulatory Affairs at RA Ventures. He spent the first 15 years in industry in low, medium, and high-throughput drug discovery, focusing primarily on ligand- and voltage-gated ion channel targets, with therapeutic potential in CNS disorders. Ned holds a PhD in biochemistry from the University of Minnesota and a BA from Carleton College.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/Matt2.png" title_text="Matt2" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" module_alignment_tablet="center" module_alignment_phone="center" module_alignment_last_edited="on|phone" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" global_colors_info="{}"]

Matt Harding, PhD

Vice President, Discovery

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]Matt Harding has over 30 years of experience in drug target selection, pre-clinical characterization, IND enabling studies, and early clinical development. Matt was a founding scientist at Vertex Pharmaceuticals in 1989, where he spent over 26 years and was involved in 20+ R&D project teams across multiple therapeutic areas. Trained as an immunologist, Matt began his career as an assistant professor at Yale Medical School before joining industry. Prior to Lusaris Therapeutics, Matt was most recently Vice President, Translational Medicine at RA Ventures where he was instrumental in the discovery of new drug candidates and support of portfolio companies, many of which are still in clinical development. Matt holds a PhD and BS from the University of Connecticut.[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/Stephen-s.png" title_text="Stephen-s" _builder_version="4.19.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" module_alignment_tablet="center" module_alignment_phone="center" module_alignment_last_edited="on|phone" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" global_colors_info="{}"]

Stephen Schneider, PhD

Vice President, CMC

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" global_colors_info="{}"]

Stephen Schneider has over 20 years’ experience in CMC development from preclinical through commercialization of small molecule and peptides across a range of therapeutic areas. Prior to joining Lusaris, Stephen served as Senior Director of Drug Substance Development at Mind Medicine and previously held positions in CMC and chemical development at G1 Therapeutics, Cempra, Kainos Medicine, and Trimeris. Stephen received a PhD in Organic Chemistry from the University of Texas at Austin and a BS in Chemistry from the University of North Carolina at Chapel Hill and is a graduate of the North Carolina School of Science and Mathematics.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/davidM.jpg" title_text="davidM" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" module_alignment_tablet="center" module_alignment_phone="center" module_alignment_last_edited="on|phone" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.19.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]

David Mister, MS

Senior Director, Clinical Operations

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" global_colors_info="{}"]

David Mister is an experienced clinical operations director with over 25 years clinical development and operations experience. David started his career in clinical development at Cocensys working on early phase development programs in CNS. He spent seven years working as a CRA and study manager for PRA International, before joining Allergan as a study manager in 2003 working in botox neurology. David spent 15 years at Allergan in management roles within clinical development, medical affairs and clinical compliance before leaving in 2019 to join Eliem Therapeutics as the Head of Clinical Operations. Since 2021, David has been in a clinical operations consulting role with Johnson & Johnson. He has a proven track record of leading phase I – IV studies across multiple therapeutic areas that have successfully brought life-enhancing pharmaceuticals, biologics, and medical devices safely and efficiently to market. David holds a BA from University of California, Santa Barbara and a MS in psychology from Walden University.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

[dov_dv_section fb_built="1" _builder_version="4.18.0" _module_preset="default" background_image="https://lusaristx.com/wp-content/uploads/2022/10/neuron-1.svg" background_size="custom" background_image_width="87%" background_image_height="87%" background_position="bottom_left" background_horizontal_offset="-100%" background_vertical_offset="-100%" custom_margin="|auto||auto|false|false" global_colors_info="{}"][et_pb_row column_structure="2_5,3_5" _builder_version="4.18.0" _module_preset="default" use_background_color_gradient="on" background_color_gradient_stops="#ffffff 0%|#ffffff 100%" background_color_gradient_overlays_image="on" width="75%" module_alignment="center" custom_margin="5%|auto|5%|auto|false|false" custom_margin_tablet="5%|auto|5%|auto|false|false" custom_margin_phone="5%|auto|5%|auto|false|false" custom_margin_last_edited="on|desktop" custom_padding="50px|50px|50px|50px|false|false" border_radii="on|16px|16px|16px|16px" global_colors_info="{}"][et_pb_column type="2_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_image src="https://lusaristx.com/wp-content/uploads/2022/10/Dan.png" title_text="Dan" _builder_version="4.18.0" _module_preset="default" width_tablet="75%" width_phone="85%" width_last_edited="on|phone" module_alignment="center" border_radii="on|250px|250px|250px|250px" global_colors_info="{}"][/et_pb_image][/et_pb_column][et_pb_column type="3_5" _builder_version="4.18.0" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.18.0" _module_preset="default" min_height="50px" custom_margin="50px||||false|false" global_colors_info="{}"]

Daniel Grau, MPhil

Chairman

[/et_pb_text][et_pb_text _builder_version="4.18.1" _module_preset="default" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"]

Daniel Grau, an experienced biotech entrepreneur and operating executive, is Chairman of the Board of Directors of Lusaris Therapeutics and currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. He is also an Advisor to HotSpot Therapeutics and recently served on the Board of Directors at Research Alliance Corporation I (merged with POINT Biopharma) and at TetraGenetics (acquired by AbCellera). Prior to Avilar, Daniel was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Early in his career, Daniel worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. Prior to management consulting, Daniel was Director of Marketing & Business Development at a clinical information technology startup. Daniel earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the humanities.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]